Cambridge, United States
2seventy bio is a progressive player in the field of immuno-oncology cell therapy, founded in 2021. With its headquarters in the United States, the company is dedicated to altering the future of cancer treatment. Their innovative approach is encapsulated in the slogan, "It’s about time we think smarter and faster than cancer."
The company's focus lies in the convergence of cancer cell metabolism, genomics, and immune responses, crafting therapies that essentially "think" as they outperform cancer's progression. By integrating deep biological insights with cutting-edge technology, 2seventy bio is striving to redefine the cancer therapy landscape.
In pursuit of its mission, 2seventy bio recently secured a substantial investment of $286.00M through an acquisition by Bristol-Meyers Squibb on 01 March 2025. This indicates a strong interest from major industry players in the biotechnology sphere, positioning the company for impactful growth and innovation in health care.
Gracell Biotechnologies
